864829-37-8

Basic information

• Product Name: 7-[4-(2-methylphenyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydrocyclohepta[b]pyridine-9-one
• Synonyms: 7-[4-(2-methylphenyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydrocyclohepta[b]pyridine-9-one
• CAS NO: 864829-37-8
• Molecular Weight: 362.472
• Mol File: 864829-37-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 7-[4-(2-methylphenyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydrocyclohepta[b]pyridine-9-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[4-(2-methylphenyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydrocyclohepta[b]pyridine-9-one(864829-37-8)
• EPA Substance Registry System: 7-[4-(2-methylphenyl)piperidine-1-carbonyl]-5,6,7,8-tetrahydrocyclohepta[b]pyridine-9-one(864829-37-8)

Safety Data

• Hazardous Substances Data: 864829-37-8(Hazardous Substances Data)

Upstream product

• 82212-02-0 4-(2-methylphenyl)piperidine hydrogen chloride salt 
• 1206229-65-3 C₁₁H₁₁NO₃ 
• 28707-60-0 8-benzylidene-5,6,7,8-tetrahydroquinoline 
• 864499-16-1 ethyl 7-iodomethyl-8-oxo-5,6,7,8-tetrahydroquinoline-7-carboxylate 
• 864499-23-0 ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate 
• 864499-10-5 ethyl 8-oxo-5,6,7,8-tetrahydroquinoline-7-carboxylate 
• 83674-75-3 1-benzyl-4-o-tolylpiperidin-4-ol 
• 821768-11-0 1,2,3,6-tetrahydro-4-(2-methylphenyl)-1-(phenylmethyl)-pyridine 
• 1206157-97-2 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylic acid monohydrochloride 
• 95-46-5 2-methylphenyl bromide 
• 56826-69-8 5,6,7,8-tetrahydro-8-quinolinone 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 932-31-0 ortho-tolylmagnesium bromide 

Relevant articles and documents

A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K + channel

A series of compounds based on 7-{[4-(2-methylphenyl)piperidin-1-yl]methyl} -6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-9-ol ((-)-8b), a potent and selective opioid receptor-like 1 (ORL1) antagonist, was prepared and evaluated using structure-activity relationship studies with the aim of removing its affinity to human ether-a-go-go related gene (hERG) K+ channel. From these studies, 101 was identified as an optimized structure with respect to ORL1 antagonist activity, and affinity to the hERG K+channel. Furthermore, 101 showed good in vivo antagonism with a wide therapeutic index in regards to adverse cardiovascular effects.